Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Altosone; Asmanex Twisthaler; Ecotone; Ecural; Elica; Elocon; Fulmeta; Mometasone furoate monohydrate; Nasonex; Novasone; Rinelon; Rivelon; SCH 32088; Uniclar

Latest Information Update: 30 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnadienediols; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Nasal polyps; Perennial allergic rhinitis; Seasonal allergic rhinitis; Sinusitis; Skin disorders
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 10 May 2018 Kyorin Pharmaceutical acquires distribution rights from MSD for mometasone for Allergic rhinitis in Japan
  • 28 Feb 2017 Merck has patent protection for mometasone (Asmanex®) in Europe and Japan (Merck Annual report 2016)
  • 15 Sep 2016 MSD and Kyorin agree to co-promote Nasonex® in Allergic rhinitis in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top